Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors

first_img Arrowhead Pharmaceuticals Inc. today announced that the board of directors appointed veteran pharmaceutical industry executive Oye Olukotun, M.D., MPH, as an independent director of the company, with a term beginning effective September 1, 2020.Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead, said, “Oye is a senior physician executive, with deep scientific and clinical development experience across broad markets. His extensive and proven track record in successfully developing products through approval, particularly with cardiometabolic products, will be of tremendous value to Arrowhead as the company advances its two important cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, into later stage development and continues to expand its broad pipeline.”“I’m thrilled to join the Board of Arrowhead Pharmaceuticals,” said Dr. Olukotun. “Arrowhead has an exciting pipeline of truly meaningful products and I’m excited to help the company demonstrate their value.”Oye Olukotun is a Mayo Clinic trained Cardiologist who currently serves as the Chief Executive Officer of CR Strategies, LLC. He served as the CEO of Epigen Pharmaceuticals, Inc. from 2014 to 2017, and Vice Chairman of CardioVax, Inc., from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun currently serves on the board of directors for Tonix Pharmaceuticals Holding Corp. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health.About Arrowhead PharmaceuticalsArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts. Community News Herbeauty7 Most Startling Movie Moments We Didn’t Realize Were InsensitiveHerbeautyHerbeautyHerbeautyA 74 Year Old Fitness Enthusiast Defies All Concept Of AgeHerbeautyHerbeautyHerbeautyWomen Love These Great Tips To Making Your Teeth Look WhiterHerbeautyHerbeautyHerbeautyIs It Bad To Give Your Boyfriend An Ultimatum?HerbeautyHerbeautyHerbeauty15 Countries Where Men Have Difficulties Finding A WifeHerbeautyHerbeautyHerbeauty9 Of The Best Family Friendly Dog BreedsHerbeautyHerbeauty Business News Name (required)  Mail (required) (not be published)  Website  Business News Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors STAFF REPORT Published on Tuesday, September 8, 2020 | 11:12 am STAFF REPORT First Heatwave Expected Next Week Your email address will not be published. Required fields are marked * Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. 75 recommended0 commentsShareShareTweetSharePin it Make a commentcenter_img Community News CITY NEWS SERVICE/STAFF REPORT Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Top of the News Subscribe More Cool Stuff STAFF REPORT Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Darrel Done BusinessVirtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadenalast_img read more

Read More →

Faculty Council meeting held April 30

first_imgOn April 30 the members of the Faculty Council approved preliminary versions of the University Extension School courses for 2014-15 and Courses of Instruction for 2014-15. They also approved changes to the Handbook for Students and a proposal to change the name of the undergraduate concentration Literature to Comparative Literature.  In addition, they continued their discussion of academic integrity and approved proposed legislation regarding this matter.The council next meets on May 14. The last regular meeting of the faculty will be on May 6.last_img read more

Read More →